胸腺肽α_1在慢性阻塞性肺疾病合并侵袭性肺曲霉菌病中的疗效观察  

Clinical Efficacy of Thymosin α_1 in Treatment of Chronic Obstructive Pulmonary Disease with Invasive Pulmonary Aspergillosis

作　　者：王印华[1] 王宝华[1] 唐明贵[1] 刘建新[1] 柴海霞[1] 浦践一[1] 

机构地区：[1]河北联合大学附属医院重症医学科,唐山063000

出　　处：《华中科技大学学报（医学版）》2014年第3期348-350,共3页Acta Medicinae Universitatis Scientiae et Technologiae Huazhong

摘　　要：目的探讨胸腺肽α1在慢性阻塞性肺疾病(COPD)合并侵袭性肺曲霉菌病(IPA)中的临床疗效,为改善临床预后提供依据。方法选择COPD合并IPA患者50例,随机分为常规组和胸腺肽组,胸腺肽组于常规治疗外加用胸腺肽α1,每日1次,共6周。两组治疗前后分别观察CD4+亚群比例、CD4+/CD8+比值水平及细胞因子IFN-γ、IL-12水平变化,观察两组人工气道保留时间,治疗第12周的治愈率、存活率。结果经治疗后,胸腺肽组CD4+、CD4+/CD8+、IFN-γ、IL-12水平均明显升高,与治疗前及与常规组治疗后比较差异均有统计学意义(均P<0.05);胸腺肽组人工气道保留天数少于常规组,而治愈率、存活率明显高于常规组,差异均有统计学意义(均P<0.05)。结论在COPD并IPA的临床治疗上,除进行抢先抗真菌治疗外,提高免疫功能可明显改善患者预后。Objective To study the clinical efficacy of thymosin α1 in the treatment of chronic obstructive pulmonary disease （COPD） with invasive pulmonary aspergillosis （IPA） in order to provide clues for improving clinical prognosis. Methods A total of 50 COPD patients with 1PA were divided into conventional treatment group and thymosin α： treatment group. Patients in the thymosin α1 treatment group were administrated with thymosin αl , once a day for 6 weeks, besides conventional treat ment. The proportion of CD4^＋ , the ratio of CD4^＋/CD8^＋ , and the levels of IFN-γ and IL-12 were detected before and after treat ment in the two groups. The duration of the artificial airway, the recovery rate and survival rate were obtained at the 12th week. Results The proportion of CD4＋ , the ratio of CD4＋/CD8＋ , and the levels of IFN-7 and IL-12 were significantly in creased in thymosin ~1 treatment group when compared with those before treatment and those in conventional treatment group （P〈0. 05 for all）. The duration of the artificial airway was less in thymosin a1 treatment group than in conventional treatment group. The recovery rate and the survival rate were much higher in thymosin a1 treatment group than in conventional treatment group （P〈0.05）. Conclusion Increasing immune function besides antifungal treatment can significantly improve the clinical prognosis of COPD patients with IPA.

关 键 词：胸腺肽Α1 慢性阻塞性肺疾病 侵袭性肺曲霉菌病 

分 类 号：R563.4[医药卫生—呼吸系统]